-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 17, Scinexis announced the signing of a strategic cooperation agreement with Hausen Pharmaceuticals, granting the latter the exclusive rights to develop and commercialize ibrexafungerp in Greater China (including Hong Kong, Macau and Taiwan).
Ibrexafungerp is a glucan synthase inhibitor, a first-in-class triterpene antifungal agent, and is considered to be a new class of broad-spectrum oral/injection antifungal drugs.
This marketing application is mainly based on the positive results of two multi-center, randomized, double-blind, placebo-controlled, phase III VANISH-303 study and VANISH-306 study.
If approved, Ibrexafungerp will be the first non-azole therapy for vulvovaginal candidiasis in more than 20 years.
Note: The original text has been deleted